Although ARVC is a rare condition, with an incidence estimated at 1 in 2,500–5,000, it is a major cause of sudden cardiac death in young, apparently healthy individuals. The disease is ...

The following is a summary of “Arrhythmogenic Right Ventricular Cardiomyopathy: the importance of biventricular strain in ...

The first-line therapy for arrhythmogenic right ventricular cardiomyopathy (ARVC) is considered to be β-blockers, which are generally well tolerated. However, findings from the Multidisciplinary ...

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of ...

which do not address the underlying genetic cause of disease. About TN-401 Gene Therapy TN-401 is an investigational AAV9-based gene therapy being developed for the treatment of ARVC due to ...

which do not address the underlying genetic cause of disease. Tenaya is conducting the RIDGE-1 Phase 1b clinical trial of TN-401 in patients with PKP2-associated ARVC. To support TN-401’s ...